These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11782030)

  • 21. A simulated sequential analysis based on data from two MRC trials.
    Donaldson AN; Whitehead J; Stephens R; Machin D
    Br J Cancer; 1993 Dec; 68(6):1171-8. PubMed ID: 8260369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Postoperative radiotherapy in non-small cell lung cancer].
    Roelandts M; Moretti L; Van Houtte P
    Cancer Radiother; 2011 Oct; 15(6-7):514-7. PubMed ID: 21820931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy for non-small cell lung cancer.
    Non-small Cell Lung Cancer Collaborative Group
    Cochrane Database Syst Rev; 2000; 2000(2):CD002139. PubMed ID: 10796867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis.
    Pignon JP; Stewart LA
    Cancer; 1996 Jun; 77(11):2413-4. PubMed ID: 8635115
    [No Abstract]   [Full Text] [Related]  

  • 25. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating a treatment effect in survival studies in which patients switch treatment.
    Branson M; Whitehead J
    Stat Med; 2002 Sep; 21(17):2449-63. PubMed ID: 12205692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
    Schäfer H; Müller HH
    Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lung cancer highlights.
    Lynch TJ
    Oncologist; 1999; 4(4):279-86. PubMed ID: 10476538
    [No Abstract]   [Full Text] [Related]  

  • 29. Silk purse in Atlanta: a commentary on SWOG 9509, an advanced non-small cell lung cancer trial.
    Gralla RJ
    Oncologist; 1999; 4(3):188-90. PubMed ID: 10394586
    [No Abstract]   [Full Text] [Related]  

  • 30. Design and sample size estimation in clinical trials with clustered survival times as the primary endpoint.
    Xie T; Waksman J
    Stat Med; 2003 Sep; 22(18):2835-46. PubMed ID: 12953283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses.
    Gu M; Lai TL
    Control Clin Trials; 1999 Oct; 20(5):423-38. PubMed ID: 10503802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
    Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
    BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
    Whitehead J; Matsushita T
    Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asymptotic simultaneous confidence intervals for many-to-one comparisons of binary proportions in randomized clinical trials.
    Schaarschmidt F; Biesheuvel E; Hothorn LA
    J Biopharm Stat; 2009; 19(2):292-310. PubMed ID: 19212881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
    Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
    JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential re-analysis of a phase-III clinical trial in non-small cell lung cancer.
    Donaldson N; Dillman RO; Wallace J; Ortiz-Hurtado A
    Eur Respir J; 2000 May; 15(5):821-7. PubMed ID: 10853843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sample size calculations for within-patient comparisons with a binary or survival endpoint.
    Law MG
    Control Clin Trials; 1996 Jun; 17(3):221-5. PubMed ID: 8877257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
    Stinchcombe TE; Zhang Y; Vokes EE; Schiller JH; Bradley JD; Kelly K; Curran WJ; Schild SE; Movsas B; Clamon G; Govindan R; Blumenschein GR; Socinski MA; Ready NE; Akerley WL; Cohen HJ; Pang HH; Wang X
    J Clin Oncol; 2017 Sep; 35(25):2885-2892. PubMed ID: 28493811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.
    Roth JA; Fossella F; Komaki R; Ryan MB; Putnam JB; Lee JS; Dhingra H; De Caro L; Chasen M; McGavran M
    J Natl Cancer Inst; 1994 May; 86(9):673-80. PubMed ID: 8158698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.